Price of Margituximab/Meganrex 4.5mg

Margetuximab is an innovative targeted monoclonal antibody that is mainly used to treat patients with HER2-positive breast cancer. It is especially suitable for patients with advanced or metastatic disease who still have disease progression after previous treatment with Herceptin (trastuzumab). Its core mechanism of action is to target the HER2 receptor and optimize the binding of Fc fragments to effector cells in the immune system, thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) and improving immune killing efficiency. Compared with traditional HER2 antibodies, margetuximab shows unique advantages in improving immune activity and delaying tumor progression.

In China, the original drug of margetuximab has been launched, but due to its short time on the market, the specific pricing and medical insurance coverage have not yet been clarified. In overseas markets, the specifications of the European and Japanese versions of the original drugs are usually 250mg/10ml*1 bottle/box, and the price is about more than 30,000 yuan. The price may change due to exchange rate fluctuations and supply channels. It should be noted that the 4.5 mg dose is only a reference for some studies or dose adjustments. There may be significant differences in pricing systems, specifications, packaging, and unit prices in different countries and regions. Therefore, patients should refer to the actual hospital or pharmacy quotation before purchasing.

There are currently no generic versions of margetuximab on the market, which means that all supplies come from original drug companies. For clinicians and patients, understanding the specifications and price information of drugs can help to rationally arrange treatment plans and economic budgets. Despite its higher price, the clinical value and potential benefits of margetuximab in the precision treatment of advanced HER2-positive breast cancer still receive widespread attention.

In general, as a new targeted treatment drug for HER2-positive breast cancer, margituximab/Meganrex has clear main indications and can provide an effective treatment option for patients who have progressed after previous Herceptin treatment.

Reference materials:https://www.margenza.com/